MCM
ALXN

Moore Capital Management’s Alexion Pharmaceuticals ALXN Stock Holding History

Moore Capital Management’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-157,292
Closed -$28.9M – 978
2021
Q2 		$28.9M Sell
157,292
-27,708
-15% -$4.76M 0.41% 49
2021
Q1 		$28.3M Buy
185,000
+115,000
+164% +$17.8M 0.36% 48
2020
Q4 		$10.9M Buy
+70,000
New +$9M 0.12% 124
2016
Q1 		– Sell
-30,000
Closed -$5.72M – 360
2015
Q4 		$5.72M Buy
+30,000
New +$5.24M 0.18% 138

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Moore Capital Management's ALXN Position: Q3 2021 in Review

Moore Capital Management sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 157,292 shares — an estimated $28.9M sold.

Moore Capital Management first reported a position in ALXN in Q4 2015 and held it in 4 quarters. The position peaked at $28.9M in Q2 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Moore Capital Management reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Moore Capital Management sold 157,292 Alexion Pharmaceuticals shares in Q3 2021, an estimated $28.9M.
  • Moore Capital Management first reported a position in Alexion Pharmaceuticals in Q4 2015 and held it in 4 quarters.
  • Moore Capital Management's Alexion Pharmaceuticals position peaked at $28.9M in Q2 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Moore Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.